Investor Presentaiton
Company overview
Financial review
2022 priorities
Appendix
References
Novartis delivers solid Q2 performance across our value drivers
Growth, cc
Group sales Q2 +5% (H1 +5%)
IM sales Q2 +5% (H1 +5%)
Sandoz sales Q2 +5% (H1 +6%)
1
Innovation
CosentyxⓇ childhood arthritic conditions approved in EU
KymriahⓇ r/r FL approved in US and EU
ScemblixⓇ Ph+ CML received positive CHMP opinion
3
Productivity, cc
Group core operating income Q2 +5% (H1 +7%)
IM core operating income Q2 +6% (H1 +6%)
IM core margin Q2 37.2%, +0.5%pts (H1 36.6%)
Sandoz core operating income Q2-4% (H1 +10%)
SG&A savings expected to increase to ~USD 1.5bn by 2024
2
ESG
4
Innovation NTDs: USD 250m R&D investment over 5 years
(Kigali declaration)
Innovation CT diversity: >USD 50m commitment over 10 years
(Beacon of Hope)
MSCI upgrades Novartis to AA: Now top quartile within the industry
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 47 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
division r/r FL - relapsed or refractory follicular lymphoma GVHD - acute and chronic graft-versus-host disease CML - chronic myeloid leukemia NTDs - Neglected tropical diseases CT Clinical trial
4 Investor Relations | Q2 2022 Results
IM - Innovative Medicines
✓ NOVARTIS | Reimagining MedicineView entire presentation